2. Academic Validation
  3. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase

Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase

  • J Med Chem. 2003 Mar 27;46(7):1116-9. doi: 10.1021/jm0204183.
Li Sun 1,  Chris Liang,  Sheri Shirazian,  Yong Zhou,  Todd Miller,  Jean Cui,  Juri Y Fukuda,  Ji-Yu Chu,  Asaad Nematalla,  Xueyan Wang,  Hui Chen,  Anand Sistla,  Tony C Luu,  Flora Tang,  James Wei,  Cho Tang
Affiliations

Affiliation

  • 1 SUGEN, Inc., 230 E. Grand Avenue, South San Francisco, California 94080, USA. connie-sun@sugen.com
PMID: 12646019 DOI: 10.1021/jm0204183
Abstract

To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a number of different basic and weakly basic analogues were designed and synthesized. 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (12b or SU11248) has been found to show the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rbeta tyrosine kinase at biochemical and cellular levels, solubility, protein binding, and bioavailability. 12b is currently in phase I clinical trials for the treatment of cancers.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z